{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:39:00Z","timestamp":1792607940160,"version":"4.5.0"},"reference-count":44,"publisher":"American Society for Clinical Investigation","issue":"19","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,8]]},"abstract":"<jats:p>Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by deficiency of the iduronate-2-sulfatase (IDS) enzyme, resulting in cellular accumulation of glycosaminoglycans (GAGs) throughout the body. Treatment of MPS II remains a considerable challenge as current enzyme replacement therapies do not adequately control many aspects of the disease, including skeletal and neurological manifestations. We developed an IDS transport vehicle (ETV:IDS) that is engineered to bind to the transferrin receptor; this design facilitates receptor-mediated transcytosis of IDS across the blood-brain barrier and improves its distribution into the brain while maintaining distribution to peripheral tissues. Here we show that chronic systemic administration of ETV:IDS in a mouse model of MPS II reduced levels of peripheral and central nervous system GAGs, microgliosis, and neurofilament light chain, a biomarker of neuronal injury. Additionally, ETV:IDS rescued auricular and skeletal abnormalities when introduced in adult MPS II mice. These effects were accompanied by improvements in several neurobehavioral domains, including motor skills, sensorimotor gating, and learning and memory. Together, these results highlight the therapeutic potential of ETV:IDS for treating peripheral and central abnormalities in MPS II. DNL310, an investigational ETV:IDS molecule, is currently in clinical trials as a potential treatment for patients with MPS II.<\/jats:p>","DOI":"10.1172\/jci.insight.145445","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T14:02:20Z","timestamp":1633615340000},"source":"Crossref","is-referenced-by-count":35,"title":["Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome"],"prefix":"10.1172","volume":"6","author":[{"given":"Annie","family":"Arguello","sequence":"first","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Meisner","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot R.","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6608-7581","authenticated-orcid":true,"given":"Hoang N.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7947-2585","authenticated-orcid":true,"given":"Ritesh","family":"Ravi","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Simms","sequence":"additional","affiliation":[{"name":"Behavioral Core, Gladstone Institute of Neurological Disease, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Lo","sequence":"additional","affiliation":[{"name":"Behavioral Core, Gladstone Institute of Neurological Disease, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Speckart","sequence":"additional","affiliation":[{"name":"Behavioral Core, Gladstone Institute of Neurological Disease, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Holtzman","sequence":"additional","affiliation":[{"name":"Behavioral Core, Gladstone Institute of Neurological Disease, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Gill","sequence":"additional","affiliation":[{"name":"Behavioral Core, Gladstone Institute of Neurological Disease, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7913-9325","authenticated-orcid":true,"given":"Darren","family":"Chan","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhsiang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Lu","family":"Chiu","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Dugas","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Fang","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel A.","family":"Lopez","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"Solanoy","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buyankhishig","family":"Tsogtbaatar","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-1378","authenticated-orcid":true,"given":"Yuda","family":"Zhu","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk R.","family":"Henne","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8124-5477","authenticated-orcid":true,"given":"Anastasia G.","family":"Henry","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Delucchi","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Harris","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-2614","authenticated-orcid":true,"given":"Dolores","family":"Diaz","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Scearce-Levie","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2620-5165","authenticated-orcid":true,"given":"Pascal E.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Denali Therapeutics Inc., South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2011.05.006"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-007-0635-4"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-1350"},{"issue":"2","key":"B4","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9020396","article-title":"Brain pathology in mucopolysaccharidoses (MPS) patients with neurological forms","volume":"9","author":"Viana","year":"2020","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041258"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1274"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-014-9686-7"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082975"},{"key":"B9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","article-title":"Treatment of brain disease in the mucopolysaccharidoses","volume":"122s","author":"Scarpa","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1359"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1163"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R110.134452"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.07.011"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035787"},{"issue":"15","key":"B15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155188","article-title":"Characterization of fluid biomarkers reveals lysosome dysfunction and neurodegeneration in neuronopathic MPS II patients","volume":"21","author":"Bhalla","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100455"},{"issue":"9","key":"B17","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbadis.2016.05.021","article-title":"Oxidative and nitrative stress and pro-inflammatory cytokines in mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation","volume":"1862","author":"Jacques","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/srep38305"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa098"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50942"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09389-8"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100549"},{"key":"B23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2017.09.007","article-title":"Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses","volume":"122S","author":"Shapiro","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-007-0641-8"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddl038"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172435"},{"issue":"9","key":"B27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86696","article-title":"CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Motas","year":"2016","journal-title":"JCI Insight"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35498"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hipo.22013"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2005.01.017"},{"issue":"8","key":"B31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/diagnostics10080554","article-title":"Hearing loss in mucopolysaccharidoses: current knowledge and future directions","volume":"10","author":"Wolfberg","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.095315"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2014.04.001"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2007.03.003"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/01.gim.0000232477.37660.fb"},{"key":"B36","unstructured":"A study of DNL310 in pediatric participants with Hunter syndrome. https:\/\/ClinicalTrials.gov. NCT04251026. Accessed September 8, 2021"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.039"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/21678707.2017.1296761"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.01.027"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-005-5673-3"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2013.03.005"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-016-0284-4"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glt046"},{"issue":"15","key":"B44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155449","article-title":"High-throughput liquid chromatography-tandem mass spectrometry quantification of glycosaminoglycans as biomarkers of mucopolysaccharidosis II","volume":"21","author":"Wang","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/145445\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:43:04Z","timestamp":1779147784000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/145445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":44,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10,8]]},"published-print":{"date-parts":[[2021,10,8]]}},"alternative-id":["10.1172\/jci.insight.145445"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.145445","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"article-number":"e145445"}}